Ascelia Pharma

About Ascelia Pharma

Ascelia Pharma is a biotech company focused on orphan oncology treatments. Their mission is to develop and commercialize novel drugs that address unmet medical needs in rare cancer conditions, aiming to improve the lives of people living with cancer by offering better treatment options. Their vision is to be a leader in identifying, developing, and commercializing such drugs.

Products & Services

Orviglance®:A drug candidate in clinical development, formerly known as Mangoral, focused on addressing unmet needs in rare cancer conditions, with a recent New Drug Application (NDA) submitted to the U.S. FDA.

Oncoral:A drug candidate in clinical development targeting rare cancer conditions as part of Ascelia Pharma's pipeline.

Specialties

Orphan Oncology Drug Development for Rare Cancer Conditions Liver Metastases Gastric Cancer

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Rights Issue T: - FT: Rights Issue	A: 105000000 MR: - FA: 105 million FAN: 105000000	D: 2024-09-30 FD: 2024-09-30	1 investors
2	RT: Convertible Debt T: - FT: Convertible Debt	A: 7500000 MR: - FA: SEK 7.5 million FAN: 7500000	D: 2024-09-13 FD: 2024-09-13	1 investors
3	RT: Rights Issue T: - FT: Rights Issue	A: 105000000 MR: - FA: SEK 105 million FAN: 105000000	D: 2024-09-05 FD: 2024-09-05	1 investors
4	RT: Rights Issue T: - FT: Rights Issue	A: 105000000 MR: - FA: approximately SEK 105 million FAN: 105000000	D: 2024-09-04 FD: 2024-09-04	-
5	RT: Rights Issue T: - FT: Rights Issue	A: 9975000 MR: - FA: SEK 105 million FAN: 9975000	D: 2024-09-01 FD: 2024-09-01	-

Rights Issue Latest

2024-09-30

$105.0M

1 investor (Pro only)

Convertible Debt 2024-09-13

$7.5M

Rights Issue 2024-09-05

$105.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Peter Benson

Chairman of the board of directors

L

Lauren Barnes

Member of the Board of Directors and Chairman of Commercialization Committee

H

Hans Maier

Member of the Board of Directors and Member of Commercialization Committee

H

Helena Wennerström

Member of the Board of Directors and Chairman of Audit Committee

M

Marianne Kock

Member of the Board of Directors and Chairman of the Remuneration Committee

M

Magnus Corfitzen

Chief Executive Officer

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

Ascelia Pharma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised